

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. Pooled mITT population characteristics by baseline EASI (n=851) ^a

Characteristic	Baseline EASI 16.0–21.0 (moderate disease)		Baseline EASI 21.1–50.0 (severe disease)		Baseline EASI >50.0 (very severe disease)	
	LEB 250 mg Q2W (n=163)	PBO (n=71)	LEB 250 mg Q2W (n=359)	PBO (n=193)	LEB 250 mg Q2W (n=42)	PBO (n=23)
Age, mean (SD)	37.7 (18.2)	36.0 (16.5)	36.0 (17.2)	34.9 (17.3)	34.0 (14.6)	29.6 (12.5)
Female, n (%)	87 (53.4)	43 (60.6)	178 (49.6)	95 (49.2)	12 (28.6) ^b	10 (43.5) ^b
Race, n (%)						
White	113 (69.3)	46 (64.8)	231 (64.3)	119 (61.7)	20 (47.6)	13 (56.5)
Asian	20 (12.3)	16 (22.5)	81 (22.6)	52 (26.9)	16 (38.1)	7 (30.4)
Black	20 (12.3)	6 (8.5)	34 (9.5)	19 (9.8)	4 (9.5)	1 (4.3)
Other ^c	10 (6.1)	3 (4.2)	13 (3.6)	3 (1.6)	2 (4.8)	2 (8.7)
Years since AD diagnosis, mean (SD)	19.5 (14.3)	18.7 (13.3)	21.5 (14.9)	23.2 (15.5)	28.1 (16.5)	20.8 (12.9)
EASI, mean (SD)	18.5 (1.5)	18.3 (1.6)	30.8 (7.3)	31.4 (7.6)	58.4 (5.5)	58.3 (5.2)
IGA, n (%)						
3 (moderate)	144 (88.3)	68 (95.8)	201 (56.0)	108 (56.0)	0 (0.0)	2 (8.7)
4 (severe)	19 (11.7)	3 (4.2)	158 (44.0)	85 (44.0)	42 (100.0)	21 (91.3)
BSA % involvement, mean (SD)	26.0 (11.2)	24.7 (9.2)	50.2 (18.9)	50.6 (18.6)	83.7 (12.0)	84.5 (10.3)

^a Pooled from the ADvocate1 ITT population and the ADvocate2 mITT population, the latter of which excluded 18 patients from a single site because their eligibility could not be confirmed.

^b Among patients with very severe baseline EASI, there was a slight imbalance between the proportion of female patients in the LEB subgroup (28.6%) vs the PBO subgroup (43.5%), likely due to the small sample sizes.

^c Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Other, Multiple, and Not Reported.

Abbreviations: AD, atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; ITT, intent-to-treat; LEB, lebrikizumab; mITT, modified intent-to-treat; PBO, placebo; Q2W, every two weeks; Q4W, every four weeks; SD, standard deviation.